In this regard, GLP-1R agonists and GLP-1 analogs (exenatide, liraglutide, and lixisenatide), used to treat diabetes, have been identified as promising drugs for PD, showing neuroprotective and neurorestorative properties. This evidence concerns the gene GLP1R and Parkinson disease.